KEGG   PATHWAY: maua05235
Entry
maua05235                   Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Mesocricetus auratus (golden hamster)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
maua05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
maua05235

Organism
Mesocricetus auratus (golden hamster) [GN:maua]
Gene
101833248  Hif1a; hypoxia-inducible factor 1-alpha isoform X1 [KO:K08268]
101830366  Egf; pro-epidermal growth factor [KO:K04357]
101838749  Egfr; epidermal growth factor receptor isoform X2 [KO:K04361] [EC:2.7.10.1]
101838968  Hras; GTPase HRas isoform X1 [KO:K02833]
101835944  Kras; GTPase KRas isoform X1 [KO:K07827]
101841999  Nras; GTPase NRas isoform X1 [KO:K07828]
121137054  GTPase NRas-like [KO:K07828]
101843997  Raf1; RAF proto-oncogene serine/threonine-protein kinase isoform X2 [KO:K04366] [EC:2.7.11.1]
101831139  Map2k1; dual specificity mitogen-activated protein kinase kinase 1 isoform X1 [KO:K04368] [EC:2.7.12.2]
101822879  Map2k2; dual specificity mitogen-activated protein kinase kinase 2 isoform X1 [KO:K04369] [EC:2.7.12.2]
101825943  Mapk1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
101841668  Mapk3; LOW QUALITY PROTEIN: mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
101831721  Fos; proto-oncogene c-Fos [KO:K04379]
101829259  Jun; transcription factor AP-1 [KO:K04448]
101837344  Eml4; echinoderm microtubule-associated protein-like 4 isoform X1 [KO:K15420]
101826367  Alk; LOW QUALITY PROTEIN: ALK tyrosine kinase receptor [KO:K05119] [EC:2.7.10.1]
101829045  Pik3r2; phosphatidylinositol 3-kinase regulatory subunit beta isoform X2 [KO:K02649]
101835039  Pik3r1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
101831400  phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
101823280  Pik3cb; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
101828739  Pik3cd; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X4 [KO:K00922] [EC:2.7.1.153]
101843471  Pik3ca; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
101825008  Pten; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
101842312  Akt2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
101825464  Akt1; RAC-alpha serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
101840296  Akt3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
101835701  Mtor; serine/threonine-protein kinase mTOR isoform X1 [KO:K07203] [EC:2.7.11.1]
101828677  Rps6kb2; ribosomal protein S6 kinase beta-2 isoform X1 [KO:K04688] [EC:2.7.11.1]
101839046  Rps6kb1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
101837015  Chuk; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
101834429  Ikbkb; inhibitor of nuclear factor kappa-B kinase subunit beta isoform X2 [KO:K07209] [EC:2.7.11.10]
101824046  Ikbkg; NF-kappa-B essential modulator isoform X1 [KO:K07210]
101835014  Nfkbia; NF-kappa-B inhibitor alpha [KO:K04734]
101831453  Nfkbib; NF-kappa-B inhibitor beta [KO:K02581]
101837689  Nfkbie; NF-kappa-B inhibitor epsilon [KO:K05872]
101839499  Nfkb1; nuclear factor NF-kappa-B p105 subunit isoform X1 [KO:K02580]
101831177  Rela; transcription factor p65 isoform X1 [KO:K04735]
101825431  Ifng; interferon gamma precursor [KO:K04687]
101827289  Ifngr1; interferon gamma receptor 1 [KO:K05132]
101828108  Ifngr2; interferon gamma receptor 2 isoform X1 [KO:K05133]
101843653  Jak1; tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
101831977  Jak2; tyrosine-protein kinase JAK2 [KO:K04447] [EC:2.7.10.2]
101827798  Stat1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
101834358  Stat3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
101838156  Tlr2; toll-like receptor 2 isoform X1 [KO:K10159]
101824088  Tlr4; toll-like receptor 4 [KO:K10160]
101844198  Tlr9; toll-like receptor 9 [KO:K10161]
101839883  toll/interleukin-1 receptor domain-containing adapter protein isoform X2 [KO:K05403]
101828578  Myd88; myeloid differentiation primary response protein MyD88 [KO:K04729]
101830563  Traf6; TNF receptor-associated factor 6 [KO:K03175] [EC:2.3.2.27]
101844781  Nfatc1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
101823473  Nfatc2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X2 [KO:K17332]
101823564  Nfatc3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
101834348  Ticam1; TIR domain-containing adapter molecule 1 [KO:K05842]
101833053  Ticam2; TIR domain-containing adapter molecule 2 [KO:K05409]
101830642  Cd274; programmed cell death 1 ligand 1 isoform X1 [KO:K06745]
101831062  Pdcd1; programmed cell death protein 1 [KO:K06744]
110340160  Ptpn6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
101833009  Ptpn11; tyrosine-protein phosphatase non-receptor type 11 isoform X1 [KO:K07293] [EC:3.1.3.48]
101842382  Batf3; basic leucine zipper transcriptional factor ATF-like 3 [KO:K09034]
101831191  Batf; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
121141382  Batf2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
121136945  casein kinase II subunit alpha'-like isoform X1 [KO:K03097] [EC:2.7.11.1]
101842272  Csnk2a2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
101826793  Csnk2a1; LOW QUALITY PROTEIN: casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
101824764  Csnk2b; casein kinase II subunit beta isoform X2 [KO:K03115]
101836856  Cd4; T-cell surface glycoprotein CD4 isoform X1 [KO:K06454]
101837225  Lck; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
101836794  Cd3e; T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
101829421  Cd3g; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
101835063  Cd247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
101836347  Cd3d; T-cell surface glycoprotein CD3 delta chain precursor [KO:K06450]
101833852  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
101832971  Map3k3; mitogen-activated protein kinase kinase kinase 3 [KO:K04421] [EC:2.7.11.25]
101838194  Map2k3; dual specificity mitogen-activated protein kinase kinase 3 isoform X1 [KO:K04432] [EC:2.7.12.2]
101833237  Map2k6; dual specificity mitogen-activated protein kinase kinase 6 isoform X1 [KO:K04433] [EC:2.7.12.2]
101824303  Mapk14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
101824910  Mapk13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
101826592  Mapk11; mitogen-activated protein kinase 11 isoform X1 [KO:K04441] [EC:2.7.11.24]
101833914  Mapk12; mitogen-activated protein kinase 12 [KO:K04441] [EC:2.7.11.24]
101825439  Lat; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
101824564  Plcg1; LOW QUALITY PROTEIN: 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116] [EC:3.1.4.11]
101833150  Ppp3cc; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
101838431  Ppp3ca; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
101840210  Ppp3cb; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
121134668  Ppp3r1; calcineurin subunit B type 1 isoform X1 [KO:K06268]
106021831  Ppp3r2; calcineurin subunit B type 2 [KO:K06268]
101844509  Rasgrp1; RAS guanyl-releasing protein 1 [KO:K04350]
101842150  Cd28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
101836283  Prkcq; protein kinase C theta type isoform X1 [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
maua04010  MAPK signaling pathway
maua04020  Calcium signaling pathway
maua04066  HIF-1 signaling pathway
maua04151  PI3K-Akt signaling pathway
maua04514  Cell adhesion molecules
maua04620  Toll-like receptor signaling pathway
maua04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system